ACTO Emerges as a Leader in Life Sciences Commercialization; Closes Strong Calendar Year 2018 with 184% Revenue Growth and Doubled Customer Base
TORONTO, Jan. 31, 2019 /PRNewswire/ - ACTO Technologies Inc. emerged as a leader in life sciences commercialization by closing a strong calendar year 2018 with 184% revenue growth and a doubled customer base. This past year, ACTO secured global, innovative pharmaceutical, medical device, and dental companies like Kala Pharmaceuticals, Teleflex, and Kulzer Dental US as clients.
"At ACTO, we are on a mission to change healthcare by disrupting how drugs and devices are commercialized in the United States and globally," said CEO Parth Khanna, "Our vision is for our customers to stand out as clear winners in the healthcare marketplace and set themselves apart in their commercialization efforts so that together, we can achieve better patient outcomes."
In 2018, ACTO enhanced its product offering and launched the world's first Commercialization Cloud for Life Sciences: A one-stop-shop sales and marketing platform that helps life sciences companies increase sales and maximize brand potential. By combining mobile learning, sales enablement, video coaching, and event management in a single, intuitive app, ACTO gives senior leaders deep visibility into successful rep behaviors, field competency gaps, and customer engagement.
After successfully using micro-learning for over three years to improve message consistency, clinical understanding, and product training for life sciences companies, this past year ACTO transformed from a mobile learning platform to a full-suite Commercialization Cloud for Life Sciences.
This transition comes in response to customer demand for consolidation of sales, training, and marketing systems when drugs and devices enter the stream of commerce, the need to consolidate various commercial applications in the fast-growing non-CRM category, and ACTO's three years of research analyzing field behaviors of over 5,700 top-performing reps and MSLs.
ACTO's innovation along the commercialization journey is already driving strategic value for senior sales, marketing, training, and medical affairs' leaders as they increase headcount and bring new products and indications to market.
The launch of the Commercialization Cloud is one among many of the company's achievements this past year in product enhancements, hiring, fundraising, and partnerships.
Other notable achievements in 2018:
For more information on ACTO's Commercialization Cloud for Life Sciences and how it's changing healthcare, visit acto.ai.
View original content to download multimedia:http://www.prnewswire.com/news-releases/acto-emerges-as-a-leader-in-life-sciences-commercialization-closes-strong-calendar-year-2018-with-184-revenue-growth-and-doubled-customer-base-300787235.html
SOURCE ACTO Technologies, Inc.